Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

26.65USD
17 Oct 2017
Change (% chg)

-- (--)
Prev Close
$26.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
822,164
52-wk High
$33.00
52-wk Low
$13.60

Select another date:

Fri, Sep 1 2017

BRIEF-Acorda adopts Shareholder Rights Plan

* Acorda Therapeutics - adopted Shareholder Rights Plan, declared a dividend distribution of 1 preferred share purchase right on each outstanding share

BRIEF-Scopia Capital Management ups its stake in Acorda Therapeutics to 18.2 pct from previous stake of 16.5 pct

* Scopia Capital Management reports 18.2 pct stake in Acorda Therapeutics Inc as of Aug 29 versus 16.5 percent stake as of Aug 4 - SEC filing Source text: (http://bit.ly/2wm9kpl) Further company coverage:

BRIEF-Acorda receives refusal to file letter from FDA for Inbrija maketing application

* Acorda receives refusal to file letter from FDA for Inbrija™ (CVT-301, Levodopa inhalation powder) new drug application

Pharma industry rallies around Acorda's appeal of patent ruling

Trade groups representing the pharmaceutical and biotech industries on Monday urged a federal appeals court to reverse a ruling that invalidated key patents held by Acorda Therapeutics Inc on its multiple sclerosis drug Ampyra.

Deals of the day-Mergers and acquisitions

Aug 7 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Acorda Therapeutics investor calls for company to explore sale

A New York-based hedge fund that owns 17 percent of Acorda Therapeutics Inc on Monday called on the U.S. developer of drugs targeting neurological disorders to explore a sale, according to a regulatory filing with the U.S. Securities and Exchange Commission.

UPDATE 1-Acorda Therapeutics investor calls for company to explore sale

Aug 7 A New York-based hedge fund that owns 17 percent of Acorda Therapeutics Inc on Monday called on the U.S. developer of drugs targeting neurological disorders to explore a sale, according to a regulatory filing with the U.S. Securities and Exchange Commission.

BRIEF-‍Scopia Capital Management LP reports 16.5 pct stake in Acorda Therapeutics as of Aug 4 - SEC filing​

* ‍Scopia Capital Management LP reports 16.5 percent stake in Acorda Therapeutics Inc as of August 4 - SEC filing​

Acorda Therapeutics investor calls for company to explore sale

Aug 7 A New York-based hedge fund which owns 17 percent of Acorda Therapeutics Inc called on the U.S. developer of drugs targeting neurological disorders on Monday to explore a sale of the company, according to a regulatory filing with the U.S. Securities and Exchange Commission.

BRIEF-Acorda Therapeutics Q2 non-GAAP earnings per share $0.29

* Acorda provides financial and pipeline update for second quarter 2017

Select another date: